MB
VRTX icon

MidFirst Bank’s Vertex Pharmaceuticals VRTX Stock Holding History

MidFirst Bank’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.5K Buy
138
+28
+25% +$12.4K ﹤0.01% 370
2026
Q1 		$49.1K Sell
110
-21
-16% -$9.79K ﹤0.01% 385
2025
Q4 		$59.4K Buy
+131
New +$56.5K ﹤0.01% 442

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

MidFirst Bank's VRTX Position: Q2 2026 in Review

MidFirst Bank increased its Vertex Pharmaceuticals (VRTX) stake by 25% in Q2 2026, buying an estimated $12.4K and bringing the position to 138 shares worth $68.5K. The position accounts for ﹤0.01% of the portfolio, ranked #370.

MidFirst Bank first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,473 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • MidFirst Bank held 138 shares of Vertex Pharmaceuticals worth $68.5K as of Q2 2026.
  • MidFirst Bank bought 28 Vertex Pharmaceuticals shares in Q2 2026, an estimated $12.4K.
  • Vertex Pharmaceuticals made up ﹤0.01% of MidFirst Bank's portfolio in Q2 2026, its #370 holding.
  • MidFirst Bank first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,473 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on MidFirst Bank's 13F filing for Q2 2026, filed 7 Aug 2026.